BioNTech Stock Under Pressure as Patent Litigation Joins Revenue Slide and Mixed Analyst Calls
Published on 07/20/2026 at 13:21 | Redaktion boerse-global.de
BioNTech’s shares are treading water near the EUR 80 mark, trapped between a dwindling COVID-19 vaccine franchise and a promising but unproven oncology pipeline, while a fresh wave of patent litigation adds to the uncertainty. After closing at EUR 80.20 on Friday, the stock edged down to EUR 80.00 on Monday, a modest 0.25% decline. It remains 5.54% below its 200-day moving average of EUR 84.85, underscoring the medium-term downtrend. The 52-week high of EUR 105.80, set on January 22, 2026, is now a distant memory.
The new legal front was opened by Arbutus Biopharma and Genevant Sciences, who have filed claims over the lipid nanoparticle technology used to deliver the mRNA in BioNTech’s COVID-19 vaccine, co-developed with Pfizer. The outcome could impose additional financial liabilities on a business already in sharp decline. Revenue has collapsed from EUR 17.3 billion at the pandemic peak in 2022 to a projected EUR 2.87 billion in 2025.
Against this backdrop, analyst opinions are far from uniform. Wall Street Zen recently upgraded the stock from "Sell" to "Hold", but other houses are moving in the opposite direction. Morgan Stanley cut its price target from $126 to $119 on July 8, though it retains an "Overweight" rating. Berenberg slashed its target from $155 to $140 in May, also maintaining a "Buy". HC Wainwright reaffirmed a $130 target and "Buy" in April, while Sanford C. Bernstein stood pat at "Market Perform" in June. The consensus stands at 14 Buy ratings (including one Strong Buy), four Holds, and a lone Sell, with price targets ranging from Morgan Stanley’s $119 to Berenberg’s $140.
Should investors sell immediately? Or is it worth buying BioNTech?
Even as analysts debate, institutional investors have been quietly adjusting positions. Larson Financial Group boosted its stake by 86.4% in the fourth quarter, albeit from a small base. Ameriprise Financial increased its holding by 1% in the second quarter, bringing its position to roughly $3.07 million. Insiders control 19.20% of shares, while institutions hold 15.52%.
The fate of the stock hinges largely on the clinical progress of two late-stage oncology candidates, Pumitamig and Gotistobart, both developed with partners. BioNTech, spun out of Johannes Gutenberg University Mainz in 2008, now employs over 2,800 people and has more than 20 product candidates in development, eight of them in clinical trials. Founders U?ur ?ahin and Özlem Türeci, awarded the Bundesverdienstkreuz in March 2021, have staked the company’s post-pandemic future on these therapies.
With vaccine revenues shrinking, legal risks mounting, and analyst opinions split, BioNTech’s shares are likely to remain range-bound until the next wave of clinical data provides a clearer direction. The market is watching, but not yet voting.
Ad
BioNTech Stock: New Analysis - 20 July
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
